AbbVie’s Allergan Aesthetics received European Commission approval for Boey (trenibotulinumtoxinE). The authorization covers all 30 European Economic Area countries.
The treatment targets moderate to severe glabellar lines, or frown lines, in adults. It is the first rapid-onset, short-duration neurotoxin approved for this indication in Europe.
Clinical studies demonstrated visible effects as early as eight hours after administration. The treatment typically lasts between two and three weeks.
Boey expands AbbVie’s aesthetics portfolio alongside Botox.